---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-127597"
form_type: "8-K"
ticker: "TAOX"
cik: "0001571934"
company_name: "TAO Synergies Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:20:03.604173+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Synaptogenix Phase 2 trial of Bryostatin-1 fails to meet primary endpoint in advanced Alzheimer's

## Summary
- Primary endpoint: change in SIB total score at week 28; Bryostatin-1 1.4 pts vs placebo 0.6 pts, not statistically significant.
- Company disappointed, conducting full data review; will provide update on next steps.
- Cash position of ~$38.5M (~$4.00 per share) as of Dec 15, 2022, provides flexibility.
- Trial was NIH-sponsored, double-blind, placebo-controlled for advanced Alzheimer's disease.

## SEC filing metadata
- accession: 0001104659-22-127597
- form_type: 8-K
- ticker: TAOX
- cik: 0001571934
- company_name: TAO Synergies Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1571934/000110465922127597/0001104659-22-127597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1571934/000110465922127597/tm2232868d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-127597
- JSON: https://secwatch.observer/filing/0001104659-22-127597.json
- Plain text: https://secwatch.observer/filing/0001104659-22-127597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.